Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome

NCT04655599 is registered in ClinicalTrials.gov with Arena Pharmaceuticals as lead sponsor.

NCT NCT04655599
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04655599 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
Lead sponsor
Arena Pharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
January 29, 2021
Completion date
April 13, 2021
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome